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Abstract 
Non-small-cell lung cancer (NSCLC) is one of the most prevalent types of lung cancer and continues to have an 
ominous five year survival rate. Considerable work has been accomplished in analyzing the viability of the treatments 
offered to NSCLC patients; however, while many of these treatments have performed better over populations of 
diagnosed NSCLC patients, a specific treatment may not be the most effective therapy for a given patient. Coupling 
both patient similarity metrics using the Gower similarity metric and prior treatment knowledge, we were able to 
demonstrate how patient analytics can complement clinical efforts in recommending the next best treatment. Our 
retrospective and exploratory results indicate that a majority of patients are not recommended the best surviving 
therapy once they require a new therapy. This investigation lays the groundwork for treatment recommendation using 
analytics, but more investigation is required to analyze patient outcomes beyond survival.   
Introduction 
Lung cancer is one of the most prevalent cancers worldwide for both men and women1, and accounts for nearly 15% 
of new cancer diagnoses2. Of the various types of lung cancer, non-small cell lung cancer (NSCLC) represents over 
80% of all documented lung cancer occurrences. Reductions in smoking have aided in the decline of death rates, but 
advanced stage diagnoses (IIIB and IV) continue to have an ominous 5-year survival rate2 (26% and 1% respectively). 
While improvements in survival will continue with the development of new treatments and therapies, large-scale 
patient analytics may provide the means for reinforcing or improving traditional recommendation methods with the 
currently available therapies.  
Traditionally, patients are administered a new line of therapy after either receiving a sufficient number of cycles or an 
unresponsive outcome to the prior treatment3. Clinicians are faced with the dilemma of selecting this new line. 
Considerable work has been accomplished in analyzing the viability of the treatments offered to NSCLC patients3; 
however, while many of these treatments have performed better over populations of diagnosed NSCLC patients, a 
specific treatment may not be the most effective therapy for a given patient. More recently, and with the growth of 
patient data digitization, the potential for performing large-scale patient analytics becomes more accessible. Patients 
are grouped together and viewed as collective target subgroups, where each patient shares the same genetic, 
demographic, clinical, and treatment profile with patients within the same group. This patient-centric, analytics 
approach allows for more patient–centric care.  
Patient similarity metrics are not a novel concept. They have been used to help quantify the relationship between 
patients, which provide practical applications and insight for a given patient based on the known outcomes of patients 
with comparable profiles. Applications utilizing similarity metrics for better patient health and well-being include the 
following: medical diagnosis4, mortality predictions5, treatment recommendations6,7 and more8. These studies 
however, do not leverage either the patients’ prior treatments or the ordering of these treatments. Prior line knowledge 
is integral in selecting the next therapy9, and has shown its value in studies beyond pure analytics applications. Using 
sequential pattern mining techniques to represent treatment features, Malhotra et al. were able to improve survival 
prediction models10. Wright el al. also used sequential pattern mining techniques on patient treatments to develop 
supervised machine-learning models to predict the next prescribed patient therapy11. These studies further prove that 
prior treatment knowledge should be considered when recommending the next treatment.  
Applying patient analytics in the treatment recommendation domain could potentially provide: 
• An analytics perspective and reference on therapy outcomes to complement traditional recommendation 
methods 
• A method for targeting clinical trial participants who may not be receptive to currently available therapies 
Perer et al has led the forefront on visualizing treatment outcomes for similar patients with the CareFlow application12. 
This data-driven, visual analytics tool recommends an entire care plan to a specific patient based from the outcomes 
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of similar patients. Using entire therapy lines, initial results for a group of similar congestive heart failure patients 
pointed to patients having a better outcome by following a care plan where the first line was different from the 
clinically recommended initial first line. While the approach is similar to our study, this work does not provide a 
detailed investigation over the impact of each line. We seek to recommend a single line of therapy based on the 
increased survival time each patient experiences using our proposed After Stem Patient Survival method (see Methods 
equation (1). To further our investigation, we varied parameters (similarity threshold and which line number is 
recommended) in the models to analyze their impact as well. Also, another key distinction is that we used genetic 
biomarker results in our study. Biomarkers are one of the most influential indicators for clinicians in recommending 
treatments and the CareFlow application provides no clear indication of using any biomarkers in their study. 
Other techniques including machine learning have been investigated in an effort to improve patient survival outcomes. 
In particular, Glioblastoma10 and NSCLC13 are two disease conditions where models were trained to predict overall 
patient survival using a myriad of patient features including therapy knowledge. Our data-driven approach using 
similarity metrics does not try to predict survival but rather investigates if better treatment recommendations exist for 
NSCLC patients using known outcomes from real world data.  
This paper proposes a novel method that incorporates not only features that are used in traditional patient profiling 
(genetic, demographic, clinical, etc…), but we also account for prior treatment history in selecting the next best 
treatment. 
Methods 
Data Source 
This study was conducted using the FlatIron® Advanced NSCLC proprietary dataset14, which aggregates genetic, 
clinical, and demographic information regarding each de-identified patient. All data available in FlatIron® dataset is 
in a structured and normalized format, including information extracted from medical notes by FlatIron® medical 
scientists. This dataset includes patients in stage IIIB or stage IV who are administered at least a single therapy on or 
after December 2010 and for which there is at least two documented EMR (Electronic Medical Record) visits during 
the same period. The FlatIron® advanced NSCLC dataset includes a geographically diverse sample of patients with a 
majority of patients treated at Community Oncology Hospitals and additional patients from Academic Centers in the 
United States.  This longitudinal study contains data from December 2010  through May 2018. The dataset includes 
the following attributes: encompassing demographic data, clinical diagnosis, laboratory data, biomarker tests and 
results, medication, line of therapy  (LOT), at the drug and class level, month and year of death, and patients’ clinical 
characteristics (i.e. stage of diagnosis, tumor histology, smoking status, and ECOG performance status). Note that this 
study does not qualify as human subjects research in accordance with the U.S. Code of Federal Regulations (CFR), 
45 CFR 46.102(f), and is thereby exempt from Institutional Review Board evaluation. 
Certain patients and lines of therapy were removed from consideration. Any therapy line begun three months before 
the official cutoff date (any line administered after March 1, 2018) was removed from the patient profile. This filtering 
ensures new therapies had a consistent amount of time to take effect. We also removed any patient who had the same 
dates for the start and end of their therapy. This uncommon occurrence results from only a single administration of 
the therapy. Our main outcome of this study is to analyze survival relating to each line and these types of 
administrations do not provide any survival duration, but are still considered a therapy administration in the FlatIron® 
database. For this reason, we removed any patient with this rare behavior. Following these exclusion criteria, 30,974 
unique patients remained. 
Feature Space 
All features listed in the dataset are partitioned into three categories: Genomic, Demographic/Clinical, and Treatment. 
The genomic features include results from well-regarded biomarker tests: ALK, EGFR, KRAS, ROS1, and PD-L115. 
The outcomes from these biomarker tests influence on the treatment decision process for clinicians, and these genetic 
features also play a critical role in our recommendation procedure. The demographic/clinical features include race, 
age, gender, presence of maintenance therapy, initial performance score, and site of metastasis. These features and 
their corresponding statistics along with the genetic biomarker tests can be found in Table 1. Altogether, there were 
23 features used in creating the patient profiles used for similarity (see non-treatment-based similarity). Although 
treatment information was used in this study, it was not included in the patient feature profile. These treatments 
generate the treatment similarity (see Treatment-Based Similarity). This study was performed at a class level analysis, 
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and each treatment was assigned a class using a hierarchy defined by FlatIron®. The line breakdown and the 
percentage of class representation across the dataset is shown in Table 2 and Figure 1 respectively.  
Table 1. Feature statistics for the genomic biomarkers and the demographic/clinical data  
Feature Feature Feature 
Gender 
-Female 
-Male 
-Unknown 
 
Race 
-White 
-Asian 
-Black/African American 
-Other 
-Hispanic/Latino 
-Unknown 
 
Time between Diagnosis and 
Advanced Diagnosis (mean) 
  
First Known ECOG 
-0 
-1 
-2 
-3 
-4 
-Unknown 
 
Region 
-Northeast 
-West 
-Midwest 
-South 
-Unknown 
 
1st Line Maintenance 
-0 
-1 
 
 
 
14547 (47.0%) 
16426 (53.0%) 
1 (~0%) 
 
 
21673 (70.0%) 
799 (2.5%) 
2566 (8.3%) 
2529 (8.2%) 
47 (0.2%) 
3360 (10.8%) 
 
5.6 ± 17.7 months 
 
 
 
7423 (24.0%) 
8428 (27.2%) 
3028 (9.8%) 
676 (2.2%) 
31 (0.1%) 
11388 (36.8%) 
 
 
6286 (20.3%) 
4502 (14.5%) 
5547 (17.9%) 
12233 (39.5%) 
2406 (7.8%) 
 
 
27929 (90.3%) 
2995 (9.7%) 
 
 
 
Biomarker Results 
-ALK Positive 
-ALK Negative 
-Unknown 
 
-EGFR Positive 
-EGFR Negative 
-Unknown 
 
-KRAS Positive 
-KRAS Negative 
-Unknown 
 
-PDL1 Positive 
-PDL1 Negative 
-Unknown 
 
-ROS1 Positive 
-ROS1 Negative 
-Unknown 
 
Stage at Diagnosis 
-Occult 
-Stage 0 
-Stage I 
-Stage IA 
-Stage IB 
-Stage II 
-Stage IIA 
-Stage IIB 
-Stage III 
-Stage IIIA 
-Stage IIIB 
-Stage IV 
-Unknown 
 
 
 
 
 
 
 
691 (2.2%) 
16882 (54.5%) 
13401 (43.3%) 
 
3222 (10.4%) 
16203 (52.3% 
11549 (37.3%) 
 
2522 (8.1%) 
6257 (20.2%) 
22195 (71.7%) 
 
1421 (4.6%) 
2778 (9.0%) 
26775 (86.4%) 
 
123 (0.4%) 
9360 (30.2%) 
21491 (69.4%) 
 
 
1 (~0%) 
1 (~0%) 
417 (1.3%) 
972 (3.1%) 
864 (2.8%) 
150 (0.5%) 
672 (2.2%) 
577 (1.9%) 
344 (1.1%) 
2152 (6.9%) 
3863 (12.5%) 
20029 (64.7%) 
932 (3.0%) 
 
 
 
Site of Metastasis 
-Liver Positive 
-Liver Negative 
 
-Lung Positive 
-Lung Negative 
 
-Brain Positive 
-Brain Negative 
 
-Adrenal Positive 
-Adrenal Negative 
 
-Lymph Node Positive 
-Lymph Node Negative 
 
-Bone Positive 
-Bone Negative 
 
-CNS Positive 
-CNS Negative 
 
-Other Positive 
-Other Negative 
 
Histology 
-Squamous 
-Non-squamous 
-Not Otherwise Specified 
 
Smoking History 
-Smoker 
-Non-Smoker 
-Unknown 
 
Age at First Line (mean) 
 
 
 
 
 
 
1642 (5.3%) 
29332 (94.7%) 
 
1323 (4.3%) 
29651 (95.7%) 
 
4287 (13.8%) 
26687 (86.2%) 
 
811 (2.6%) 
30163 (97.4%) 
 
1611 (5.4%) 
29313 (94.6%) 
 
8001 (25.8%) 
22973 (74.2%) 
 
264 (0.9%) 
30710 (99.1%) 
 
2539 (8.2%) 
28435 (91.8%) 
 
 
7618 (24.6%) 
21780 (70.3%) 
1576 (5.1%) 
 
 
26476 (85.5%) 
4092 (13.2%) 
406 (1.3%) 
 
66.9 ± 9.8  yrs 
 
 
 
 
 
 
Table 2. Number of patients having at least the 
number of lines in their TS 
Line Number of patients 
1 30974 
2 13579 
3 5345 
4 2111 
5 787 
6 290 
7 132 
8 52 
9 19 
10 5 
11 2 
12 2 
13 2 
 
Definitions 
Let D represent the set of drugs received by patients. A treatment, also referred to as a line of therapy (LOT), is an 
administration received by a patient over a specified time period. A treatment sequence (TS) is a series of LOTs 
received by a patient in a sequential manner to indicate the order in which the treatments were  administered. For 
Figure 1. Class percentage breakdown 
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example, a patient P that took a series of three therapies (A, B, and C) in D, patient P’s TS is defined and represented 
as the following:  “A BC” where A is the first LOT, B the second, and C the third. In this representation, all 
LOT’s are separated by arrows. 
Primary Outcomes 
Given a group of similar patients Simp to a patient P, recommend a treatment corresponding to the subgroup of patients 
having the “best” outcome following the same treatment stem sequence (prior treatments). More formally, the stem is 
the entire TS before the recommended LOT. For patient P, if we want to recommend a fourth LOT, the TS from the 
first line A to third line C would be considered the stem.   
This study uses patient line survival as the primary outcome. After Stem Patient Survival (ASPS) and its corresponding 
calculation, define the “best” outcome in our study. The following paragraphs provide more details on the ASPS 
definitions and how the method determines the similar patient subgroups and treatment stems. 
ASPS: Is defined as the percent time duration from the start of the next LOT after the treatment stem sequence until 
either death or last known treatment end date (computed in days) divided by the overall survival (also computed in 
days). More formally, given P and the set of similar patients Simp, let “t1 t2…tk” be the TS of patient P used as 
the stem treatment sequence to find patients with similar previous treatment as P.  
In the example of Figure 3, this treatment stem sequence corresponds to (AB). If Pi is a patient in Simp, then we 
define the treatment sequence of Pi as “ti1 ti2…tij…tik tik+1…tin”. In this case, the ASPS of patient Pi 
in Simp, noted ASPS (Pi) is defined by the following equation, where duration (tij) is the time duration of the LOT tij. 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(𝐴𝐴𝑃𝑃) = ∑ 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷(𝐷𝐷𝑖𝑖𝑖𝑖)𝑛𝑛𝑖𝑖=𝑘𝑘+1
∑ 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷(𝐷𝐷𝑖𝑖𝑖𝑖)𝑛𝑛𝑖𝑖=1                                                                  (1) 
In the example of Figure 3, ASPS (P1) is the ratio of the duration of the sum of the treatment durations of the LOTs  D 
and E (100 days) and the overall survival of patient P1 (250). 
Methodology Pipeline 
Given a “reference” patient P described by a set of demographic, genetic, clinical characteristics, and a set of already 
prescribed treatments, our approach is to recommend the next treatment for patient P by finding the treatment sequence 
administered to similar patients that led to the “best” outcome.  In this study, the best outcome is determined using 
line therapy survival. Figure 2 depicts the main steps involved in our approach. 
 
Figure 2. Proposed methodology pipeline  
Non-Treatment-Based Similarity 
We divide the set of patient features into two categories: genetic and clinical/demographic. We first compute the 
similarity between patients for each category and then combine the two similarity measures using a geometric mean 
calculation. A similar approach for combining multiple patient similarity metrics was used in a study by Gottlieb et 
al4. We compute the similarity between patients within each category using the Gower Similarity Coefficient16 given 
its design to incorporate both continuous and binary features. The resulting similarity matrix is then used to determine 
the set of similar patients above a pre-defined similarity threshold w.r.t a single reference patient. When calculating 
the similarity between patients, only features where both patients have valid entries are considered. If one of the 
patients has a null feature, this feature is ignored for the purposes of non-treatment-based similarity. 
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Treatment-Based Similarity 
Given a reference patient P, we first compute a set of similar patients Simp (determined from the genetic and 
clinical/demographic features). The next step is to filter from Simp the patients that do not share the same stem (prior 
treatments) as the reference patient. The objective is to consider only patients who share similar previous treatments 
in order to determine the next treatment for the reference patient. An example illustrating this filtering is depicted in 
Figure 3. Treatments are represented as letters, while arrows represent the sequencing of treatments. Patients 4 and 6 
are filtered from further consideration as they do not share the same treatment stem in their sequence as the reference 
patient. 
 
Figure 3. Example illustration of the algorithm recommending treatment D using line survival as the sole outcome 
Next Treatment Recommendation 
After the two-step filtering process, only patients who share a common treatment stem and have a similarity above a 
required threshold with the reference patient remain. From this subset of patients, we determine the percentage of each 
patient’s survival following the treatment stem. Once this value is computed, we average the percentage across all 
patients with the same next treatment following the stem. This process is detailed in Figure 3 and shows that the 
percentage of survival is only computed for the subgroup (Patients 1,2,3,5, and 7) that share the same treatment stem 
(AB).  All percentage of patients sharing the same next treatment after the stem are then averaged together (48% 
for D, 46.5% for F, and 43% for E), which results in the algorithm selecting treatment D as the best next treatment for 
the patient.  
To formally describe how we recommend the next treatment, consider the following definitions. Let Pt1, Pt2, …, Pti, 
… Ptm be m subsets of patients from Simp such that, patients in subset Pti share the same next LOT ti following the 
stem treatment sequence. In the example of Figure 3, patients P1 and P3 belong to the same subset sharing the same 
next line of therapy D.  
The equation below details the method for averaging the ASPS for each m subset in Simp: Max
𝐷𝐷=1…𝑚𝑚(∑ 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(𝐴𝐴𝑖𝑖)|𝑃𝑃𝑡𝑡𝑖𝑖|𝑖𝑖=1 |𝐴𝐴𝑡𝑡𝑖𝑖| )                                                                        (2) 
The next treatment belonging to the subset of patients containing the highest average ASPS is selected as the “best” 
next treatment. 
Evaluation 
To evaluate the performance of our approach, we propose to consider a portion of patients in the dataset as a reference 
patient. Given that the patient survival time is known, we can compute the number of times that the recommended 
treatment would have led to a longer survival than the reference patient’s original survival time. In our proposed 
implementation, we divide the dataset into ten random subsets (with replacement following the entire selection of a 
subset), compute the performance of the approach for each sample, and then average the performance across all 
samples. We also analyze the impact of previous (i.e. stem) treatment knowledge on the performance of the method 
and the selection of the similarity threshold. 
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Results 
Altogether, there were 30,974 patients considered in this study. First, we separated ten random 300 patient subsets 
with replacement (a patient may not appear more than once in a same subset but may or may not be represented in 
another subset). As a baseline, we evaluated each subset of patients using the methodology proposed above, but 
without any prior treatment knowledge (0-stem). Each patient in this subset was evaluated against the other 30,674 
patients. After each subset evaluation was complete, the results were aggregated together. We repeated this process 
with the 0-stem length five different times considering different minimum similarity thresholds each evaluation (0.65, 
0.7, 0.75, 0.8, 0.85). The results are displayed below. 
Table 3. Results from evaluating the treatment recommendation algorithm with five different thresholds for zero prior treatments 
(0-Stem). The similarity threshold is listed along with the percentage representing the likelihood where a reference patient in the 
random subset was recommended a better different therapy than the one the patient took. The most and least frequent 
recommendations are also listed.  
Similarity 
Threshold 
Percent of Patients 
Recommended a 
“better” treatment 
Most Common 
Recommended 
Treatment Class 
Least 
Recommended 
Treatment Class 
0.85 69.8% Clinical Study Drug 
(22.3%) 
PDL1 Therapies 
(1.7%) 
0.8 69.3% Clinical Study Drug 
(23.3%) 
PDL1 Therapies 
(0.9%) 
0.75 72.7% Other Therapies 
(27.0%) 
PDL1 Therapies 
(0.3%) 
0.7 72.7% Other Therapies 
(40.6%) 
PDL1 Therapies 
(0.2%) 
0.65 72.8% Other Therapies 
(44.3%) 
PDL1 Therapies 
(0.1%) 
 
After the 0-stem baseline, we then repeated the same process with all five similarity thresholds for both 1-stem and 2-
stem subsets. 1-Stem ensures all treatment recommendations are from therapies following whichever therapy was the 
first line of the reference patient. 2-Stem follows a similar format but with two therapies. Figure 3 above illustrates 
the evaluation for a 2-stem process. The results for both 1-stem and 2-stem are found below in Table 4 and Table 5. 
Table 4. Results from evaluating the treatment recommendation algorithm with five different thresholds with a single line prior 
treatment knowledge (1-Stem). The similarity threshold is listed along with the percentage representing the likelihood where a 
reference patient in the random subset was recommended a better different therapy than the one the patient took. The most and 
least frequent recommendations are also listed.   
Similarity 
Threshold 
Percent of Patients 
Recommended a 
“better” treatment 
Most Common 
Recommended 
Treatment Class 
Least 
Recommended 
Treatment Class 
0.85 66.5% Platinum-Based 
Chemo (17.8%) 
Other Therapies 
(2.6%) 
0.8 68.1% Clinical Study Drug 
(19.5%) 
Other Therapies 
(4.5%) 
0.75 72.1% Clinical Study Drug 
(22.3%) 
Single Agent Chemo 
(2.0%) 
0.7 71.6% Clinical Study Drug 
(26.3%) 
Single Agent Chemo 
(1.0%) 
0.65 71.2% Clinical Study Drug 
(22.3%) 
Single Agent Chemo 
(0.3%) 
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Table 5. Results from evaluating the treatment recommendation algorithm with five different thresholds with a two line prior 
treatment knowledge (2-Stem). The similarity threshold is listed along with the percentage representing the likelihood where a 
reference patient in the random subset was recommended a better different therapy than the one the patient took. The most and 
least frequent recommendations are also listed.   
Similarity 
Threshold 
Percent of Patients 
Recommended a 
“better” treatment 
Most Common 
Recommended 
Treatment Class 
Least 
Recommended 
Treatment Class 
0.85 62.9% PDL1 Therapies 
(21.6%) 
Other Therapies 
(0.9%) 
0.8 64.1% PDL1 Therapies 
(19.9%) 
Other Therapies 
(0.6%) 
0.75 68.5% Anti-VEGF 
Therapies (18.6%) 
Other Therapies 
(1.9%) 
0.7 74.9% Clinical Study Drug 
(19.6%) 
Other Therapies 
(3.9%) 
0.65 77.4% Clinical Study Drug 
(20.3%) 
Other Therapies 
(4.2%) 
 
Discussion 
Discussion of Results 
These results indicate a majority of patients are not taking the next best treatment once they need to switch to a different 
therapy. For all three stem lengths and five similarity thresholds, more than 50% of patients were recommended a 
better therapy for survival.  Moreover, the length of stem and similarity threshold impacted the likelihood in which a 
patient was recommended a better therapy. In particular, for all the three stems, we found that as the similarity 
threshold increased (the subgroups of patients providing recommendations collectively are more similar to the 
reference patient), the likelihood a patient was recommended a better therapy decreased. Only two thresholds at the 
1-stem length (0.7 and 0.75) produced an increase in the likelihood of recommending a better therapy. Additionally, 
larger stem lengths (more prior knowledge), decrease this likelihood. The likelihood of recommending a better therapy 
decreased for all stem lengths and similarity thresholds except for the 2-stem length at the 0.7 and 0.65 thresholds. 
These results are intuitive. We would expect to determine a better next treatment after already considering the 
outcomes of the prior therapies. In addition, as the similarity threshold decreases, the considerations for what 
constitutes as a similar patient is reduced, which in turn may produce recommendations that may not be the most 
appropriate for a given patient. However, there is a tradeoff with high similarity thresholds. Higher thresholds will 
produce more refined groups of patients to consider, but more refinement means less patients are considered in the 
analysis. In order to compensate for the lower amounts of patients, larger datasets should be used in determining the 
“best” treatment recommendation. 
The other takeaway from these investigative results is recommendations from the drug class of Clinical Study and 
Other Therapies reduced as the similarity threshold increased. This also indicates the grouping of patients are 
becoming more refined and following more consistent standards-of-care, as most of the therapies considered in these 
two classes are either unique, new, or not yet approved therapies. Moreover, Clinical Study was the most 
recommended therapy class throughout this investigation (eight of the fifteen studies recommended this class). The 
identity of the treatments in this class are unknown which hinder any further investigation that may provide insight 
into which clinical study drugs are providing the largest impact. However, this encouraging result supports many of 
the promising clinical study results, and offers hope for many of the potential treatments for NSCLC patients in the 
future. 
Limitations 
Certain limitations do exist with this study and must be considered. First, many patients did not have complete feature 
profiles. In particular, 10,190 of the patients used in the study had no record of any biomarker results, and out of the 
remaining patients, the average patient only had between two and three results of the five biomarkers (2.86 average). 
For the patients with no biomarker information, this proved challenging as there is no genetic similarity that can be 
determined with these patients. In these cases, the similarity was determined using only the demographic and clinical 
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features. Along with the lack of genetic features, 1,927 patients contained gaps in the lines of therapy. For most 
patients, once the end of the line occurs, the next line begins. For the few patients with gaps, the beginning of the next 
line may not occur until months after the end of the last line. In this study we accounted for these gaps in the overall 
survival computation of the ASPS, however it is not the same as a typical treatment sequence of many the other 
patients. Additionally, while certain demographic features such as race, gender, and region were included in the 
similarity computation, no formal analysis of potential cofounders was investigated. 
Second, there is no comprehensive knowledge of why certain patients were administered given therapies. In our model, 
we use survival time as the sole outcome, whereas with some patients, quality-of-life or even cost of treatment is more 
important than the potential to live longer. Future applications of this work should investigate collective outcomes. In 
addition, this is a retrospective analysis. Many patients at the beginning of the study may not have had access to newly 
approved therapies or promising clinical study treatments. This may be why the model appears to be very inclined to 
recommend clinical study drugs for all the tested stem lengths.  
Lastly, there is no effective way to represent living patients. If the living patients are removed, the data becomes biased 
to only represent deceased patients. On the other hand, if you keep the living patients, their total survival becomes 
underestimated, as they are yet to complete their entire treatment pathway. In the case of our study, we included the 
living patients and represented their ending survival as the last day of the data cutoff. Altogether, there were 9,765 
living patients in the study. Any future researcher interested in applying similar work must consider the impact of 
living patients.  
Future Work 
Future work will center upon developing a composite outcome that accounts for more than patient survival (quality 
of life, cost, etc…). This will aid in representing what the clinician believes is the best next treatment for a given 
patient. In addition, as more genetic biomarkers are discovered and reported, the model will be adjusted in order to 
account for any new discoveries.  
Conclusion 
Prior treatment knowledge plays a pivotal role in the selection of the next treatment for a patient. Using prior treatment 
knowledge along with patient similarity metrics, we proposed a methodology for recommending the next treatment. 
The “best” outcome for a given patient was determined by selecting the best percentage survival following the same 
administered treatment from a subgroup of similar patient. Our initial investigative evaluations indicated that while 
many patients are not taking the best next treatment for survival, the likelihood that a patient took the best next 
treatment increases as the subgroups are refined closer to the given patient or the target patient has a longer prior 
treatment history. Further investigation is necessary in order to validate these findings.  
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